LLY — ELI LILLY & Co catalysts
Next verified catalyst
2026-09-01 — A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic · official source ↗
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-09 (month) in 26d
ESTIMATED |
READOUT
A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity an
Phase 2 · Overweight, Obesity |
LLY ELI LILLY & Co | Tirzepatide |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09 (month) in 26d
ESTIMATED |
READOUT
A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (
Phase 3 · Perennial Allergic Rhinitis (PAR) |
LLY ELI LILLY & Co | LY3650150, Standard therapy for INCS |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10 (month) in 2mo
ESTIMATED |
READOUT
A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Y
Phase 3 · Systemic Juvenile Idiopathic Arthritis |
LLY ELI LILLY & Co | Baricitinib, Tocilizumab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10 (month) in 2mo
ESTIMATED |
READOUT
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes
Phase 3 · Type 2 Diabetes |
LLY ELI LILLY & Co | Retatrutide |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-11 (month) in 3mo
ESTIMATED |
READOUT
A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea
Phase 3 · OSA, Overweight or Obesity |
LLY ELI LILLY & Co | Orforglipron |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-11 (month) in 3mo
ESTIMATED |
READOUT
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults
Phase 3 · Obesity |
LLY ELI LILLY & Co | Retatrutide, Tirzepatide |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-11 (month) in 3mo
ESTIMATED |
READOUT
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 D
Phase 3 · Type 1 Diabetes, Obesity |
LLY ELI LILLY & Co | Tirzepatide |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-11 (month) in 3mo
ESTIMATED |
READOUT
A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and
Phase 3 · Type 1 Diabetes, Obesity |
LLY ELI LILLY & Co | Tirzepatide |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-11 (month) in 3mo
ESTIMATED |
READOUT
A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated Wit
Phase 2 · Diabetes Mellitus, Type 2 |
LLY ELI LILLY & Co | LY3938577, Degludec |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-11 (month) in 3mo
ESTIMATED |
READOUT
A Study of LY4515100 in Participants With Pain Following Third Molar Removal
Phase 2 · Acute Pain, Molar |
LLY ELI LILLY & Co | LY4515100 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-12 (month) in 4mo
ESTIMATED |
READOUT
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes
Phase 2 · Type 2 Diabetes |
LLY ELI LILLY & Co | LY3457263 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-12 (month) in 4mo
ESTIMATED |
READOUT
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by
Phase 2 · Nausea, Vomiting |
LLY ELI LILLY & Co | LY3537021, Background Chemotherapy |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
Past
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-08-04 2d ago
CONFIRMED |
APPROVED
FOUNDAYO
|
LLY ELI LILLY & Co | FOUNDAYO |
openFDA (drugsfda) ↗
✓ Source-checked 2026-08-06
Actual/recorded date
|